Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trials; the plans and objectives of management for future operat ...

Xencor (XNCR) Update / Briefing April 29, 2025 05:00 PM ET Speaker0 Welcome to today's R and D call hosted by Xencor. At this time, all participants are in a listen only mode. After the speakers' presentation, we will conduct a question and answer session. I will now turn the call over to your host, Charles Lyles, Senior Director of Corporate Communications and Investor Relations. Speaker1 Thank you, and good afternoon. Earlier today, we issued a press release announcing positive interim results from our Ph ...

Xencor (XNCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often find it ...

Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.30%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.98 per share when it actually produced a loss of $0.71, delivering a surprise ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________________________________________ ...

Financial Position - Xencor has a strong financial position with approximately $707 million in cash, cash equivalents, and marketable debt as of December 31, 2024[9]. Drug Development Pipeline - The company is advancing three novel T-cell engagers (TCEs) in Phase 1 studies focused on oncology, specifically targeting metastatic castration-resistant prostate cancer (mCRPC) and first-line non-small cell lung cancer (NSCLC)[7]. - XmAb942 (Xtend™ TL1A) is set to initiate studies in Q4 2024, while Plamotamab (CD20xCD3) is expected to enter Phase 1 in the first half of 2025[7]. - XmAb819 (ENPP3 x CD3) is currently in a Phase 1 dose escalation study for clear cell renal cell carcinoma (ccRCC), showing promising initial data with no maximum tolerated dose reached[21]. - XmAb541 (CLDN6 x CD3) is also in Phase 1, demonstrating high selectivity for CLDN6 over similar proteins, targeting ovarian and endometrial cancers[23]. - XmAb808 (B7-H3 x CD28) is in Phase 1, designed to enhance selective T cell activation in solid tumors, with ongoing patient enrollment[35]. - XmAb942 and XmAb TL1A x IL-23 are in development for ulcerative colitis, leveraging validated half-life extension technology[75]. - The first-in-human clinical study for XmAb942 is planned to initiate in Q4 2024[29]. - The initiation of Phase 1/2 study for Plamotamab (CD20 x CD3) in rheumatoid arthritis is set to begin[95]. - XmAb942 is expected to have single ascending dose (SAD) and multiple ascending dose (MAD) readouts in the immunology portfolio[95]. - XmAb717-04 and XmAb717-05 expansion readouts are anticipated in 1H 2025[93]. - The first-in-class potential for XmAb TL1A x IL-23 is being explored with a study planned for 2026[82]. Technology and Innovation - The company has a robust patent portfolio with over 1,600 patents issued and pending worldwide, enhancing its competitive edge in the market[7]. - Xencor's drug development strategy emphasizes rapid prototyping and strict evaluation of data to maximize outcomes for stakeholders[9]. - The company’s Xtend™ Fc technology has shown to significantly improve half-life and dosing frequency compared to traditional antibodies[77]. - XmAb942 utilizes Xtend™ Fc domain technology with a half-life of 23 days, supporting dosing every 8 to 12 weeks[29]. Collaborations and Market Strategy - The company is exploring technology licensing to expand its pipeline with minimal opportunity cost, indicating a strategic approach to market expansion[13]. - Xencor's collaborations with Johnson & Johnson focus on prostate cancer combinations, leveraging access to J&J's resources for enhanced development[34]. Market Opportunities - Current market for rheumatoid arthritis treatments exceeds $20 billion, with unmet needs for moderate-to-severe systemic lupus erythematosus (SLE) estimated at over $5 billion in the US[44]. - The global IBD drug market is projected to exceed $23 billion by 2030, highlighting significant unmet medical needs in inflammatory bowel disease[72]. - The bispecific antibody class is positioned to address significant limitations in current autoimmune disease treatments, with ongoing studies supporting its efficacy[43]. Clinical Outcomes - Vudalimab, a dual checkpoint inhibitor (PD-1 x CTLA-4), has shown a low rate of treatment discontinuation due to adverse events in ongoing studies[91]. - Vudalimab monotherapy has demonstrated clinical responses in 5 out of 12 evaluable patients with metastatic castration-resistant prostate cancer (mCRPC)[93]. - XmAb drug candidates are advancing with multiple dose expansions planned, including XmAb819 and XmAb808 in oncology[95]. - The company aims to evaluate the safety of Vudalimab in combination with chemotherapy for non-small cell lung cancer (NSCLC)[93]. - XmAb657, designed for autoimmune diseases, has demonstrated over 90% reduction in B-cell counts in both bone marrow and whole blood across dose cohorts[56]. - Plamotamab, a subcutaneous CD20 x CD3 bispecific antibody, is planned for Phase 1b/2a study initiation in the first half of 2025, focusing on rheumatoid arthritis[58].

Xencor (XNCR) has been on a downward spiral lately with significant selling pressure. After declining 21.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...

A downtrend has been apparent in Xencor (XNCR) lately with too much selling pressure. The stock has declined 20.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spottin ...

Xencor (XNCR) has been beaten down lately with too much selling pressure. While the stock has lost 23.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measur ...

Xencor (XNCR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...